- Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
- Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
- PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
- Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
On Friday, PAVmed Inc (PAVM:NAQ) closed at 2.12, 32.50% above the 52 week low of 1.60 set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.24 |
---|---|
High | 2.33 |
Low | 2.11 |
Bid | 2.02 |
Offer | 2.35 |
Previous close | 2.25 |
Average volume | 59.03k |
---|---|
Shares outstanding | 9.43m |
Free float | 8.77m |
P/E (TTM) | -- |
Market cap | 20.00m USD |
EPS (TTM) | -9.24 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼